Non-small cell lung cancer Trials in Xiamen, China
Conditions / Non-small cell lung cancer / Xiamen, China
Non-small cell lung cancer has been the subject of sustained clinical investigation across multiple research sites.
38 total trials for this combination
Showing top 10 of 38 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | RECRUITING | — |
| NCT04928846 | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02005458 | Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy | COMPLETED | PHASE2 |
| NCT05671510 | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | RECRUITING | — |
| NCT06345729 | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | RECRUITING | — |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | RECRUITING | PHASE1/PHASE2 |
| NCT03800134 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06698042 | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |